Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1 US2016008189A1
DISPOSABLE DIAPER WITH POCKET CONTAINING ONE OR MORE WIPES
Publication/Patent Number: US2016008189A1 Publication Date: 2016-01-14 Application Number: 14/798,874 Filing Date: 2015-07-14 Inventor: Ezzo, Louis Ronald   Ezzo, Elsa Bernice   Assignee: EZZO, LOUIS RONALD   EZZO, ELSA BERNICE   IPC: A61F13/84 Abstract: The invention provides a disposable diaper with a pocket containing one or more sanitary wipes. The pocket is constructed on the outer layer of the diaper and provides a closed, moisture-impermeable chamber within which one or more moistened wipes are stored. The pocket can include perforations, perforation strips or a tear strip that allows the user to open the pocket and access the one or more wipes by tearing. The invention provides a disposable diaper with a pocket containing one or more sanitary wipes. The pocket is constructed on the outer layer of the diaper and provides a closed, moisture-impermeable chamber within which one or more moistened wipes are stored. The pocket can ...More ...Less
2 US2016008250A1
Compositions and methods of reducing dry mouth
Publication/Patent Number: US2016008250A1 Publication Date: 2016-01-14 Application Number: 14/859,691 Filing Date: 2015-09-21 Inventor: Cohen, Marvin   Cohen, Susanne   Flynn, Robert   Assignee: The Research Foundation for the State University of New York   IPC: A61K8/49 Abstract: Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier. Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an ...More ...Less
3 US2016008257A1
HAIR CARE COMPOSITIONS CONTAINING POLYELECTROLYTE COMPLEXES
Publication/Patent Number: US2016008257A1 Publication Date: 2016-01-14 Application Number: 14/773,038 Filing Date: 2014-03-14 Inventor: Zhou, Yan   Rigoletto, Raymond   Foltis, Linda C.   Qu, Xin   Colaco, Allwyn   Assignee: ISP INVESTMENTS INC.   IPC: A61K8/81 Abstract: Disclosed herein is an aqueous hair care composition capable of providing durable non-permanent hair styling and/or wash-resistant retention of shape of hair fibers comprising a polyelectrolyte complex having a gel matrix structure or a mixture of gel matrix and microgel formed by electrostatic attraction, wherein the polyelectrolyte complex comprises a complex between: (A) about 0.01 wt. % to about 20 wt. % of at least one anionic polymer containing monoacid, diacid, triacid, half-acid/half-ester, acid anhydride functionality, or salts thereof having a molecular weight of from about 100,000 Daltons to about 5000,000 Daltons; and (B) about 0.1 wt. % to about 20 wt. % of at least one cationic or pseudo cationic polymer having a (i) molecular weight range of about 80,000 Daltons to about 5,000,000 Daltons, and (ii) a charge density of less than about 4.0 meg/gram, and wherein, the charge ratio of (B):(A) is more than about 0.70. Disclosed herein is an aqueous hair care composition capable of providing durable non-permanent hair styling and/or wash-resistant retention of shape of hair fibers comprising a polyelectrolyte complex having a gel matrix structure or a mixture of gel matrix and microgel formed ...More ...Less
4 US2016008259A1
Tritightening skin care formulation
Publication/Patent Number: US2016008259A1 Publication Date: 2016-01-14 Application Number: 13/998,617 Filing Date: 2013-11-18 Inventor: Zecchino, Julius   Assignee: Zecchino, Julius   IPC: A61K8/88 Abstract: The present invention provides for a formulation comprising: at least one hydrophilic polymer, at least one desquamatory agent and alpha hydroxyl acid.
5 US2016008264A1
Volume boosting molding hair coloring creme formulation
Publication/Patent Number: US2016008264A1 Publication Date: 2016-01-14 Application Number: 14/545,925 Filing Date: 2015-07-08 Inventor: Greene, Michael V.   Assignee: Greene, Michael V.   IPC: A61K8/97 Abstract: An improved hair color formulation treats hair to provide volume, viscosity, color and hair follicle stimulation. The color formulation is appointed to be used in hair products, and comprises a natural color agent and at least one agent providing anti-dihydrotestosterone (DHT) effects. Hair products include styling products, cleansing products, concealment products, and dying products. In one embodiment, the formulation comprises an aqueous emulsion, at least one hydrocarbon, at least one thickening agent, at least one humectant, at least one emollient, at least one fatty acid ester, and at least one agent providing anti-dihydrotestosterone (DHT) effects, such as caffeine, and at least one color agent. Preservatives, fibers and further treatments for male/female pattern baldness may also be added to the composition. Natural colorants are added to the hair color formulation to provide temporary coloring in addition to enhanced volume, viscosity and hair follicle stimulation. An improved hair color formulation treats hair to provide volume, viscosity, color and hair follicle stimulation. The color formulation is appointed to be used in hair products, and comprises a natural color agent and at least one agent providing anti-dihydrotestosterone (DHT) ...More ...Less
6 US2016008270A1
COSMETIC COMPOSITIONS AND METHODS OF THEIR USE
Publication/Patent Number: US2016008270A1 Publication Date: 2016-01-14 Application Number: 14/796,104 Filing Date: 2015-07-10 Inventor: Gan, David   Jacoby, Patricia   Assignee: Mary Kay Inc.   IPC: A61K8/99 Abstract: Described herein are compositions useful for moisturizing and/or improving the appearance of skin by evening skin tone and/or reducing the appearance of dark spots or hyperpigmentation. The compositions comprise cosmetic ingredients such as lactobacillus ferment; Ferula foetida root extract; Helianthus annuus (sunflower) seed extract; Terminalia ferdinandiana fruit extract, and niacinamide. Described herein are compositions useful for moisturizing and/or improving the appearance of skin by evening skin tone and/or reducing the appearance of dark spots or hyperpigmentation. The compositions comprise cosmetic ingredients such as lactobacillus ferment; Ferula foetida ...More ...Less
7 US2016008277A1
CO-PACKAGED DRUG PRODUCTS
Publication/Patent Number: US2016008277A1 Publication Date: 2016-01-14 Application Number: 14/795,403 Filing Date: 2015-07-09 Inventor: Crystal, Roger   Weiss, Michael Brenner   Assignee: Lightlake Therapeutics Inc.   IPC: A61K9/00 Abstract: Provided herein are drug products comprising a combination of an opioid receptor agonist and an opioid receptor agonists, including co-packaged drug products comprising an opioid receptor agonist and an opioid receptor antagonist in a delivery device selected from a hand-held auto-injector and a pre-primed nasal delivery device, and methods of prescribing and dispensing same. Methods of lowering opioid overdose risk by providing a combination of an opioid receptor agonist and an opioid receptor agonists, for example by co-packaging an opioid receptor agonist and an opioid receptor antagonist in a delivery device, are also provided. Provided herein are drug products comprising a combination of an opioid receptor agonist and an opioid receptor agonists, including co-packaged drug products comprising an opioid receptor agonist and an opioid receptor antagonist in a delivery device selected from a hand-held ...More ...Less
8 US2016008286A1
BUPRENORPHINE NANOPARTICLE COMPOSITION AND METHODS THEREOF
Publication/Patent Number: US2016008286A1 Publication Date: 2016-01-14 Application Number: 14/378,706 Filing Date: 2013-02-21 Inventor: Ravis, William R.   Lin, Yuh-jing   Assignee: Auburn University   IPC: A61K9/16 Abstract: Stable nanoparticle compositions comprising buprenorphine and at least one biodegradable polymer. The disclosure also provides methods of controlling pain in an animal and methods of treating addiction in a human utilizing the stable nanoparticle compositions, as well as pharmaceutical formulations comprising the stable nanoparticle compositions. The stable nanoparticle compositions are capable of releasing buprenorphine over several days, weeks, or months following administration. The stable nanoparticle compositions of buprenorphine utilize biodegradable polymers capable of degrading into non-toxic components in the body of an animal and may be excreted in the urine of the animal following their metabolism in the body. The stable nanoparticle compositions can advantageously provide sustained release of buprenorphine in the body after a single administration without the need for surgical removal of implanted matrices subsequent to depletion of the drug. Stable nanoparticle compositions comprising buprenorphine and at least one biodegradable polymer. The disclosure also provides methods of controlling pain in an animal and methods of treating addiction in a human utilizing the stable nanoparticle compositions, as well as ...More ...Less
9 US2016008289A1
Tetrary Gene Delivery System for Gene Therpay and Methods of Its Use
Publication/Patent Number: US2016008289A1 Publication Date: 2016-01-14 Application Number: 14/859,661 Filing Date: 2015-09-21 Inventor: Xu, Peisheng   Kc, Remant Bahadur   Assignee: UNIVERSITY OF SOUTH CAROLINA   IPC: A61K9/50 Abstract: Delivery systems and their methods of formation are generally provided. The delivery system can protect a delivery molecule (e.g., DNA/RNA) and deliver it into a cell via serum. In one embodiment, the method can include binding a delivery molecule with polyethylenimine such that an end of the delivery molecule is exposed; capping the end of the delivery molecule with a first biocompatible polymer to form a core; and encapsulating the core with a second biocompatible polymer. The resulting delivery system can include a delivery molecule bonded with polyethylenimine such that an end of the delivery molecule is exposed; a first biocompatible polymer electrostatically bonded to the end of the delivery molecule to form a core; and a second biocompatible polymer encapsulating the core. Delivery systems and their methods of formation are generally provided. The delivery system can protect a delivery molecule (e.g., DNA/RNA) and deliver it into a cell via serum. In one embodiment, the method can include binding a delivery molecule with polyethylenimine such that ...More ...Less
10 US2016008297A1
COMPOUNDS FOR PREVENTING, REDUCING AND/OR ALLEVIATING ITCHY SKIN CONDITION(S)
Publication/Patent Number: US2016008297A1 Publication Date: 2016-01-14 Application Number: 14/435,906 Filing Date: 2012-08-23 Inventor: Schmaus, Gerhard   Krohn, Michael   Sombroek, Dirk   Haustedt, Lars Ole   Kluge, Grit   Koch, Oskar   KÖhler, Antje   Assignee: B.R.A.I.N. Biotechnology Research And Information Network AG   IPC: A61K31/12 Abstract: The present invention primarily relates to the use of one or more specific compounds and/or one or more respective salt(s) thereof for preventing, reducing or alleviating itchy skin condition(s), and/or as PAR-2 antagonist. Furthermore, the present invention relates to compositions (products or, respectively, formulations), in particular for topical administration, preferably cosmetic or pharmaceutical compositions, in particular for preventing, reducing or alleviating one or more itchy skin conditions and/or for providing a PAR-2 antagonistic effect, comprising or consisting of an effect amount of such compound(s) and/or salt(s) and one or more cosmetically and/or pharmaceutically acceptable carriers. The present invention primarily relates to the use of one or more specific compounds and/or one or more respective salt(s) thereof for preventing, reducing or alleviating itchy skin condition(s), and/or as PAR-2 antagonist. Furthermore, the present invention relates to ...More ...Less
11 US2016008298A1
XANTHOHUMOL-BASED COMPOUNDS AND COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME
Publication/Patent Number: US2016008298A1 Publication Date: 2016-01-14 Application Number: 14/798,393 Filing Date: 2015-07-13 Inventor: Stevens, Jan Frederik   Assignee: Oregon State University   IPC: A61K31/12 Abstract: Disclosed herein are compounds capable of ameliorating, treating, and preventing metabolic syndrome, or risk factors associated with metabolic syndrome, such as obesity, diabetes, and/or cardiovascular disease. In some embodiments, the compounds can function as mild mitochondrial uncouplers and thereby reduce markers of metabolic syndrome by improving insulin sensitivity and glucose metabolism. Methods of making the compounds also are disclosed herein, along with compositions and formulations suitable for administration to a subject. In some embodiments, the compounds (or compositions thereof) can be formulated and administered as dietary supplements. Disclosed herein are compounds capable of ameliorating, treating, and preventing metabolic syndrome, or risk factors associated with metabolic syndrome, such as obesity, diabetes, and/or cardiovascular disease. In some embodiments, the compounds can function as mild ...More ...Less
12 US2016008299A1
NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS
Publication/Patent Number: US2016008299A1 Publication Date: 2016-01-14 Application Number: 14/630,357 Filing Date: 2015-02-24 Inventor: Ferchmin, Peter Andrew   Eterovic, De Ferchmin Vesna Ana   Maldonado, Hector Manuel   El, Sayed Khalid   Assignee: Ferchmin, Peter Andrew   Eterovic De Ferchmin, Vesna Ana   Maldonado, Hector Manuel   El Sayed, Khalid   IPC: A61K31/122 Abstract: A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis. A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically ...More ...Less
13 US2016008309A1
USE OF TRANS-PALMITOLEATE IN IDENTIFYING AND TREATING METABOLIC DISEASE
Publication/Patent Number: US2016008309A1 Publication Date: 2016-01-14 Application Number: 14/516,421 Filing Date: 2014-10-16 Inventor: Mozaffarian, Dariush   Cao, Haiming   Hotamisligil, Gokhan S.   Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE   IPC: A61K31/201 Abstract: The present invention provides for a novel lipokine, trans-C16:ln 7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:ln 7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:ln 7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism. The present invention provides for a novel lipokine, trans-C16:ln 7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:ln 7-palmitoleate the serum indicates a risk of metabolic disease. Additionally ...More ...Less
14 US2016008312A1
BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES
Publication/Patent Number: US2016008312A1 Publication Date: 2016-01-14 Application Number: 14/863,784 Filing Date: 2015-09-24 Inventor: Nelson, Andrea   Chen, Quin-zene   Mehta, Harsh   Tu, Yu-hsing   Assignee: TRIS Pharma Inc.   IPC: A61K31/245 Abstract: A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release ...More ...Less
15 US2016008318A1
A COMPOSITION FOR ENHANCING NEWBORN INFANT COGNITIVE, BRAIN AND/OR CNS DEVELOPMENT AND METHOD OF USING SAME
Publication/Patent Number: US2016008318A1 Publication Date: 2016-01-14 Application Number: 14/771,719 Filing Date: 2014-03-13 Inventor: Lai, Chron-si   Kuchan, Matthew   Assignee: ABBOTT LABORATORIES   IPC: A61K31/355 Abstract: Disclosed are nutritional compositions generally, and infant formulas specifically, that include a combination of RRR-alpha tocopherol, fat, and protein. The amount of non-RRR alpha tocopherol stereoisomers in the nutritional compositions is limited Also disclosed are methods of using the compositions to improve cognitive, brain and/or central nervous system development in an individual. Disclosed are nutritional compositions generally, and infant formulas specifically, that include a combination of RRR-alpha tocopherol, fat, and protein. The amount of non-RRR alpha tocopherol stereoisomers in the nutritional compositions is limited Also disclosed are methods of ...More ...Less
16 US2016008334A1
Preparations for the Treatment of Sleep-Related Respiratory Disorders
Publication/Patent Number: US2016008334A1 Publication Date: 2016-01-14 Application Number: 14/772,958 Filing Date: 2014-03-05 Inventor: Knutsen, Lars Jacob Stray   Hand, James M.   Assignee: REQUIS PHARMACEUTICALS INC.   IPC: A61K31/4402 Abstract: The present invention is directed to combinations of sedating antihistamines and at least one, and preferably two or more dietary supplements, which can be indole-based, such as tryptophan, 5-hydroxytryptophan, serotonin, N-acetyl-5-hydroxytryptamine and melatonin, and to their use for treating and thereby improving the health and quality of life of those suffering from sleep-related respiratory disorders, characterized by abnormal breathing during sleep. These include snoring, sleep disordered breathing, sleep apneas, upper airway resistance syndrome, obstructive sleep apnea, central sleep apnea and obesity hypoventilation syndrome and associated ailments. The present invention is directed to combinations of sedating antihistamines and at least one, and preferably two or more dietary supplements, which can be indole-based, such as tryptophan, 5-hydroxytryptophan, serotonin, N-acetyl-5-hydroxytryptamine and melatonin, and to their ...More ...Less
17 US2016008339A1
PSORALEN DERIVATIVES FOR PREVENTING OR TREATING HEART FAILURE OR CARDIAC HYPERTROPHY
Publication/Patent Number: US2016008339A1 Publication Date: 2016-01-14 Application Number: 14/412,446 Filing Date: 2013-07-02 Inventor: Klussmann, Enno   Troger, Jessica   Rosenthal, Walter   Assignee: MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN   IPC: A61K31/4433 Abstract: The present invention relates to compound characterized by a general formula 1, wherein R1 is a aryl or a heteroaryl, and —R2 and R3 independently of each other are hydrogen or a C1-C5 alkyl, but at least one of R2 and R3 is not hydrogen, or together are a C3 or C4 alkyl forming a 5- or 6 membered ring, for use in a method for treating of heart failure, hypertension, cardiac hypertrophy or cancer. The present invention relates to compound characterized by a general formula 1, wherein R1 is a aryl or a heteroaryl, and —R2 and R3 independently of each other are hydrogen or a C1-C5 alkyl, but at least one of R2 and R3 is not hydrogen, or together are a C3 or C4 alkyl ...More ...Less
18 US2016015959A1
Carrier Assembly with Caps for Medical Connectors
Publication/Patent Number: US2016015959A1 Publication Date: 2016-01-21 Application Number: 14/811,494 Filing Date: 2015-07-28 Inventor: Solomon, Donald D.   Kennedy, James Paul   Assignee: Catheter Connections, Inc.   IPC: A61M39/20 Abstract: An assembly for mounting medical connector caps includes a carrier formed from a sheet of material and having an array of holes. The assembly also includes a plurality of medical connector caps. Each cap is inserted into one of the holes of the array. The assembly also includes a plurality of sealing tabs. The tabs may be retained on the carrier by friction fit into the holes of the carrier. The carrier may also include a mounting hole to hang on a pole of an IV line. An assembly for mounting medical connector caps includes a carrier formed from a sheet of material and having an array of holes. The assembly also includes a plurality of medical connector caps. Each cap is inserted into one of the holes of the array. The assembly also includes ...More ...Less
19 US2016015967A1
SYSTEMS AND METHODS FOR MAKING AND USING ELECTRODE CONFIGURATIONS FOR PADDLE LEADS
Publication/Patent Number: US2016015967A1 Publication Date: 2016-01-21 Application Number: 14/866,054 Filing Date: 2015-09-25 Inventor: Pianca, Anne Margaret   Peterson, David Karl Lee   Assignee: Boston Scientific Neuromodulation Corporation   IPC: A61N1/05 Abstract: A paddle lead assembly for providing electrical stimulation of patient tissue includes a paddle body having a longitudinal axis and a lateral axis transverse to the longitudinal axis. The paddle body includes a plurality of electrodes disposed into at least four columns extending parallel with the longitudinal axis. The at least four columns include two lateral columns and at least two medial columns disposed therebetween. The electrodes of the at least two medial columns are arranged into rows aligned along the transverse axis. The electrodes of the two lateral columns are each longitudinally offset from the rows of electrodes of the at least two medial columns. An array of terminals are disposed on each of at least one lead body coupled to the paddle body. A plurality of conductive wires couple each of the electrodes to at least one terminal of the terminal arrays. A paddle lead assembly for providing electrical stimulation of patient tissue includes a paddle body having a longitudinal axis and a lateral axis transverse to the longitudinal axis. The paddle body includes a plurality of electrodes disposed into at least four columns ...More ...Less
20 US2016015971A1
NANOSECOND PULSED ELECTRIC FIELDS CAUSE MELANOMAS TO SELF-DESTRUCT
Publication/Patent Number: US2016015971A1 Publication Date: 2016-01-21 Application Number: 14/869,286 Filing Date: 2015-09-29 Inventor: Nuccitelli, Richard   Beebe, Stephen J.   Schoenbach, Karl H.   Assignee: Eastern Virginia Medical School   Old Dominion University Research Foundation   IPC: A61N1/20 Abstract: Methods for a new, drug-free therapy for treating solid skin tumors through the application of nanosecond pulsed electric fields (“nsPEFs”) are provided. In one embodiment of the invention, the cells are melanoma cells, and the applied nsPEFs penetrate into the interior of tumor cells and cause tumor cell nuclei to rapidly shrink and tumor blood flow to stop. This new technique provides a highly localized targeting of tumor cells with only minor effects on overlying skin. Methods for a new, drug-free therapy for treating solid skin tumors through the application of nanosecond pulsed electric fields (“nsPEFs”) are provided. In one embodiment of the invention, the cells are melanoma cells, and the applied nsPEFs penetrate into the ...More ...Less